Andere Sprachen Xbrane Biopharma AB

Aktien

A2ADY1

SE0007789409

XBRANE

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:53 26.04.2024			% 5 Tage	% 1. Jan.
0,2135 ^SEK	-1,39 %		-39,35 %	-97,86 %

22.04.	Transcript : Xbrane Biopharma AB - Special Call
26.02.	Transcript : Xbrane Biopharma AB, 2023 Earnings Call, Feb 26, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Xbrane provides regulatory update on FDA review of its ranibizumab biosimilar candidate	21.04.
Notice of annual general meeting in Xbrane Biopharma AB	02.04.
Change of number of shares and votes in Xbrane	01.04.
XBRANE BIOPHARMA RELEASES ANNUAL AND SUSTAINABILITY REPORT FOR 2023	27.03.
Xbrane resolves on a directed issue of shares to guarantors in connection with the completed rights issue	19.03.
Xbrane Biopharma AB(OM:XBRANE) dropped from S&P Global BMI Index	18.03.
Xbrane announces the outcome of the rights issue	14.03.
Xbrane publish supplement to prospectus	08.03.
Xbrane has received additional subscription undertakings corresponding to approximately SEK 18.1 million in the Company's rights issue	04.03.
Xbrane Biopharma Q4 2023 - Navigating muddy waters	01.03.
Trading in unit rights and BTUs in Xbrane's rights issue will commence on 29 February 2024	27.02.
Xbrane publishes prospectus in connection with the company’s partially guaranteed rights issue of approximately SEK 343 million	27.02.
Xbrane Biopharma releases Year-end Report 2023	26.02.
Xbrane Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26.02.
Xbrane Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	26.02.
Announcement from Extra General Meeting in Xbrane Biopharma AB	22.02.
Invitation to presentation of Xbrane Biopharma’s Year-end report 2023 on February 26, 2024	21.02.
Xbrane sends shareholder letter in connection with the proposed rights issue	05.02.
Notice of Extra General Meeting in Xbrane Biopharma AB	22.01.
Xbrane announces a rights issue of units of approximately SEK 343 million	22.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Xbrane Biopharma AB

Aktien

A2ADY1

SE0007789409

XBRANE

Andere Sprachen

Filter